Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P09958
UPID:
FURIN_HUMAN
Alternative names:
Dibasic-processing enzyme; Paired basic amino acid residue-cleaving enzyme
Alternative UPACC:
P09958; Q14336; Q6LBS3; Q9UCZ5
Background:
Furin, known as a Dibasic-processing enzyme, plays a pivotal role in cellular mechanisms, cleaving substrates at the RX(K/R)R motif. It is essential in activating TGFB1, crucial for TGF-beta-1 signaling, and processes various prohormones and viral proteins, indicating its versatile function in both physiological and pathophysiological contexts.
Therapeutic significance:
Understanding the role of Furin could open doors to potential therapeutic strategies. Its involvement in the activation of pathogens and cellular proteins underlines its potential as a target in treating infectious diseases and disorders related to protein processing.